Conditions: Cardiovascular Disease
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much of the study drug, evacetrapib, enters the blood stream and how long it takes the body to dispose of the study drug when given to participants with severe renal (kidney) impairment compared to participants with normal renal (kidney) function. This study will last approximately 8 weeks.

Detailed description:

Arms:
arm 1: Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment. arm 2: Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.

Interventions: intervention 1: Evacetrapib
Intervention descriptions: intervention 1: None

Protocol document: